Northwestern Scientists Discover Novel Mechanism for Gene Expression Control, Offering Hope for Adrenal Disease Treatments
A groundbreaking discovery by Northwestern Medicine researchers sheds new light on the intricate process of gene expression, potentially paving the way for innovative treatments for adrenal diseases.
Published in Science Advances, the study reveals a previously unknown mechanism involving the ARMC5 protein, which acts as a quality control checkpoint for RNA polymerase II (Pol II), the enzyme responsible for synthesizing RNA during gene expression.
"Think of ARMC5 as a cellular janitor," explains Dr. Yuki Aoi, assistant professor of Medicine and Biochemistry and Molecular Genetics at Northwestern and lead author of the study. "When Pol II, the enzyme responsible for reading DNA and creating RNA, malfunctions, ARMC5 steps in to identify and eliminate these defective complexes, ensuring that only properly functioning copies continue the gene expression process."
Previous research by Dr. Ali Shilatifard, the Robert Francis Furchgott Professor and chair of Biochemistry and Molecular Genetics, established that the protein SPT5 acts as a checkpoint in transcription elongation. However, the identity of the protein responsible for degrading defective Pol II remained a mystery.
Using advanced proteomic screening and genome-wide analysis, Dr. Aoi’s team identified ARMC5 as the crucial player. When SPT5 is absent, ARMC5 recognizes faulty Pol II complexes and triggers their degradation, preventing errors in gene expression.
"This discovery is significant because it provides a deeper understanding of how cells maintain the accuracy of gene expression, a fundamental process essential for all cellular functions," Dr. Aoi emphasizes.
The findings also have profound implications for understanding adrenal diseases. ARMC5 mutations are known to cause adrenal hypoplasia, a condition characterized by underdeveloped adrenal glands and hormone imbalances.
"While we previously knew ARMC5 mutations were linked to adrenal hypoplasia, we lacked a clear understanding of how these mutations disrupt normal adrenal gland development," Dr. Aoi explains. "Our research suggests that ARMC5 mutations may interfere with the proper regulation of gene expression in adrenal cells, leading to developmental defects."
This discovery opens new avenues for developing targeted therapies for adrenal hypoplasia and potentially other diseases linked to defective gene expression.
"Understanding the precise molecular pathways affected by ARMC5 mutations in adrenal hypoplasia could guide the development of therapies aimed at restoring normal gene expression in affected cells," Dr. Aoi concludes.
Funding for this research was provided by the National Cancer Institute Outstanding Investigator award R35-CA197569 and the National Institute of General Medical Sciences grant R24GM137786 (IDeA National Resource for Quantitative Proteomics).